Rapid detection of SARS-CoV-2 antibodies using flow cytometry

Several classes of antibodies against the receptor binding domain (RBD) of the SARS-CoV-2 spike protein have been identified in COVID-19 patients, and are largely responsible for the protective immunity induced by the current COVID-19 vaccines. These antibodies have potent neutralizing activity, and three isotypes (IgG, IgM, and IgA) of anti-SARS-CoV-2 spike RBD antibodies have been identified in patients following natural infection with SARS-CoV-2 or immunization with the COVID-19 vaccine.

In this webinar, join Dr. Julie Lovchik, Scientist at Sartorius, as she introduces a newly developed flow cytometry kit, which provides a rapid, robust, and sensitive serological assay for the measurement of IgG, IgM, and IgA anti-SARS-CoV-2 spike RBD antibodies.